For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Research and development | 3,621,000 | 3,474,000 | 2,205,000 | 3,298,000 |
| General and administrative | 3,561,000 | 3,954,000 | 2,708,000 | 3,623,000 |
| Total operating expenses | 7,182,000 | 7,428,000 | 4,913,000 | 6,921,000 |
| Interest income | - | 26,250* | - | - |
| Other (expense) income, net | -19,000 | - | - | - |
| Interest expense, related party | 433,000 | 358,250* | - | - |
| Interest (expense) income | - | - | -212,000 | -110,000 |
| Change in fair value of warrants | - | 0* | - | - |
| Foreign exchange gain | - | 1,000 | 2,000 | -12,000 |
| Total other expenses | -452,000 | -331,000 | -210,000 | -122,000 |
| Net loss and comprehensive loss | -7,634,000 | -7,759,000 | -5,123,000 | -7,043,000 |
| Unrealized loss on available-for-sale securities | - | - | - | 0 |
| Total comprehensive loss | - | - | - | -7,043,000 |
| Basic EPS | -2.99 | -3.033 | -2.01 | -2.76 |
| Diluted EPS | -2.99 | -3.033 | -2.01 | -2.76 |
| Basic Average Shares | 2,552,429 | 2,558,267 | 2,552,429 | 2,552,429 |
| Diluted Average Shares | 2,552,429 | 2,558,267 | 2,552,429 | 2,552,429 |
Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc. (APTOF)